Key Highlights

  • Ultragenyx shares are up 9.48% pre-market at $28.73, extending Tuesday's 2.94% gain.
  • The FDA granted Accelerated Approval for GENGLYCOS, the company's first-ever gene therapy and fifth overall product approval.
  • GENGLYCOS treats glycogen storage disease type Ia, an ultra-rare metabolic disorder affecting 1,500 to 2,500 patients in the US.
  • The approval came ahead of the FDA's August 23 target date and includes a Priority Review Voucher that could be monetized or used for future pipeline programs.

Ultragenyx Surges on First Gene Therapy Approval

Ultragenyx Pharmaceutical (NASDAQ:RARE) shares are up 9.48% in pre-market trading on August 20, extending Tuesday's 2.94% gain, after the FDA granted accelerated approval for GENGLYCOS, the company's first-ever gene therapy approval and fifth overall product approval.

Ultragenyx is a Novato, California-based biopharmaceutical company founded in 2010 and led by CEO Emil D. Kakkis, dedicated to identifying, developing, and commercializing novel therapies for serious rare and ultra-rare genetic diseases with high unmet need. Its commercial portfolio includes four approved products, Crysvita, Mepsevii, Dojolvi, and Evkeeza, generating Recurring Revenue through direct sales and collaboration and Royalty arrangements, alongside a diverse pipeline spanning gene therapy, antisense oligonucleotide, and enzyme replacement modalities.

GENGLYCOS Targets Underlying Cause of Rare Metabolic Disorder

GENGLYCOS, also known as DTX401, treats glycogen storage disease type Ia in adult and pediatric patients eight years and older. The ultra-rare genetic metabolic disorder is caused by a deficiency of the enzyme needed to release glucose from the liver to the bloodstream, requiring patients to follow a burdensome, around-the-clock regimen of raw cornstarch intake to manage glucose levels and avoid potentially life-threatening hypoglycemia. The condition affects 1,500 to 2,500 patients in the US and 6,000 to 8,000 worldwide within commercially accessible geographies.

The approval was based on positive data from the 48-week, randomized, double-blind, placebo-controlled Phase 3 GlucoGene study, which treated 46 participants with DTX401 or placebo and showed a reduction in cornstarch requirements among the treated group. The approval, which arrived ahead of the FDA's August 23 target date, resolves a key overhang for the stock amid investor uncertainty over the regulatory decision and grants Ultragenyx a Priority Review Voucher that could be monetized or applied to future pipeline programs.

What This Means for Investors

Management is hosting an investor call the evening of the approval to discuss the milestone, which comes as validation of Ultragenyx's rare disease gene therapy platform following a prior FDA rejection of its UX111 program earlier this year. With GENGLYCOS now commercial, the more important signal for investors may be less about this single approval and more about whether it de-risks the regulatory pathway for the rest of the company's gene therapy pipeline, including DTX301, UX143, and GTX-102.